Burning Rock Biotech (NASDAQ:BNR) Trading Up 1.5% – Here’s Why

Burning Rock Biotech Limited (NASDAQ:BNR)’s stock price was up 1.5% during trading on Monday . The company traded as high as $3.39 and last traded at $3.28. Approximately 21,939 shares were traded during trading, an increase of 4% from the average daily volume of 20,997 shares. The stock had previously closed at $3.23.

Burning Rock Biotech Stock Performance

The stock has a market cap of $35.30 million, a price-to-earnings ratio of -1.09 and a beta of 0.72. The business has a fifty day simple moving average of $3.34 and a 200 day simple moving average of $5.22.

Burning Rock Biotech (NASDAQ:BNR) last issued its earnings results on Tuesday, March 25th. The company reported ($1.08) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.32. The business had revenue of $17.27 million for the quarter. Burning Rock Biotech had a negative return on equity of 60.68% and a negative net margin of 83.50%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Burning Rock Biotech stock. Crcm LP bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 325,969 shares of the company’s stock, valued at approximately $2,200,000. Burning Rock Biotech comprises approximately 0.9% of Crcm LP’s portfolio, making the stock its 5th biggest holding. Crcm LP owned 3.18% of Burning Rock Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.